Nouvelle classification des cancers pulmonaires: Application aux prélèvements biopsiques de petite taille

Annales de Pathologie

Volumn 30, Issue 5 SUPPL.1, 2010, Pages 60-63

  Brambilla, Elisabeth ^a   Lantuejoul, Sylvie ^b  

^a HÔPITAL MICHALLON   (France)

^b INSTITUT ALBERT BONNIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ARTICLE; BIOPSY; CLASSIFICATION; HUMAN; LUNG TUMOR; METHODOLOGY; PATHOLOGY;

ADENOCARCINOMA; BIOPSY; HUMANS; LUNG NEOPLASMS;

EID: 79953763922     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annpat.2010.07.033     Document Type: Conference Paper

References (11)

1. Yim J., Zhu L.C., Chiriboga L., Watson H.N., Goldberg J.D., Moreira A.L. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol 2007, 20:233-241.
2. Ou S.H., Zell J.A. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009, 4:1202-1211.
3. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
4. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
5. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol;5:442-7.
6. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol;5:436-41.
7. Camilo R., Capelozzi V.L., Siqueira S.A., Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol 2006, 37:542-546.
8. Wu M., Wang B., Gil J., Sabo E., Miller L., Gan L., et al. p63 and TTF-1 immunostaining A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol 2003, 119:696-702.
9. Khayyata S., Yun S., Pasha T., Jian B., McGrath C., Yu G., et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009, 37:178-183.
10. Motoi N., Szoke J., Riely G.J., Seshan V.E., Kris M.G., Rusch V.W., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32:810-827.
11. Girard N., Deshpande C., Lau C., Finley D., Rusch V., Pao W., et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33:1752-1764.